Jubilant Pharmova Limited
Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment o… Read more
Jubilant Pharmova Limited (JUBLPHARMA) - Total Assets
Latest total assets as of September 2025: ₹135.21 Billion INR
Based on the latest financial reports, Jubilant Pharmova Limited (JUBLPHARMA) holds total assets worth ₹135.21 Billion INR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Jubilant Pharmova Limited - Total Assets Trend (2004–2025)
This chart illustrates how Jubilant Pharmova Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Jubilant Pharmova Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Jubilant Pharmova Limited's total assets of ₹135.21 Billion consist of 28.0% current assets and 72.0% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹0.00 | 8.5% |
| Accounts Receivable | ₹8.93 Billion | 7.0% |
| Inventory | ₹11.29 Billion | 8.9% |
| Property, Plant & Equipment | ₹0.00 | 0.0% |
| Intangible Assets | ₹10.97 Billion | 8.6% |
| Goodwill | ₹25.41 Billion | 19.9% |
Asset Composition Trend (2004–2025)
This chart illustrates how Jubilant Pharmova Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jubilant Pharmova Limited's current assets represent 28.0% of total assets in 2025, a decrease from 42.9% in 2004.
- Cash Position: Cash and equivalents constituted 8.5% of total assets in 2025, up from 2.6% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 27.0% of total assets, an increase from 1.0% in 2004.
- Asset Diversification: The largest asset category is goodwill at 19.9% of total assets.
Jubilant Pharmova Limited Competitors by Total Assets
Key competitors of Jubilant Pharmova Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Jubilant Pharmova Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Jubilant Pharmova Limited generates 0.57x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Jubilant Pharmova Limited generates $6.58 in net profit.
Jubilant Pharmova Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.66 | 1.80 | 2.10 |
| Quick Ratio | 1.07 | 1.20 | 1.32 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₹13.71 Billion | ₹ 15.55 Billion | ₹ 25.50 Billion |
Jubilant Pharmova Limited - Advanced Valuation Insights
This section examines the relationship between Jubilant Pharmova Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.99 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 10.5% |
| Total Assets | ₹127.56 Billion |
| Market Capitalization | $614.47 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jubilant Pharmova Limited's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Jubilant Pharmova Limited's assets grew by 10.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Jubilant Pharmova Limited (2004–2025)
The table below shows the annual total assets of Jubilant Pharmova Limited from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | ₹127.56 Billion | +10.46% |
| 2024-03-31 | ₹115.48 Billion | +3.51% |
| 2023-03-31 | ₹111.57 Billion | +11.67% |
| 2022-03-31 | ₹99.91 Billion | +12.03% |
| 2021-03-31 | ₹89.18 Billion | -28.78% |
| 2020-03-31 | ₹125.22 Billion | +9.18% |
| 2019-03-31 | ₹114.69 Billion | +19.24% |
| 2018-03-31 | ₹96.18 Billion | +6.38% |
| 2017-03-31 | ₹90.41 Billion | +1.05% |
| 2016-03-31 | ₹89.47 Billion | +3.65% |
| 2015-03-31 | ₹86.32 Billion | -2.58% |
| 2014-03-31 | ₹88.61 Billion | +5.08% |
| 2013-03-31 | ₹84.32 Billion | +7.47% |
| 2012-03-31 | ₹78.46 Billion | +3.73% |
| 2011-03-31 | ₹75.64 Billion | +10.83% |
| 2010-03-31 | ₹68.25 Billion | +3.35% |
| 2009-03-31 | ₹66.04 Billion | +56.88% |
| 2008-03-31 | ₹42.09 Billion | +29.79% |
| 2007-03-31 | ₹32.43 Billion | +58.09% |
| 2006-03-31 | ₹20.51 Billion | +62.46% |
| 2005-03-31 | ₹12.63 Billion | +45.21% |
| 2004-03-31 | ₹8.70 Billion | -- |